Approval · Notice of Compliance 29215 · 2022
VEKLURY: Notice of Compliance 29215
Issued October 14, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
Issued with conditions (NOC/c): the company must confirm the benefit in further studies.
- Notice number
- 29215
- Date
- October 14, 2022
- Company
- Gilead Sciences Canada IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- To provide Chemistry and Manufacturing data in fulfillment of quality conditions outlined in the Notice of Compliance with Conditions (NOC/c) - Qualifying Notice (QN) dated 27 July 2020.
- With conditions
- Yes (NOC/c)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| VEKLURY | Not yet assigned | — |
Medicinal ingredients
- REMDESIVIR 100 MG per VIAL